Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus
Abstract Background Hydroxychloroquine (HCQ) is an antimalarial drug, recently used in COVID-19 treatment. Also it is considered over many years the cornerstone in treating systemic lupus erythematosus (SLE) in adults and children. The incidence of retinal affection and retinal toxicity from hydroxy...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
SpringerOpen,
2021-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|